What happened with the FDA and compounded GLP-1s, and who is still operating legally?

The situation with the FDA and compounded GLP-1s has been complex, driven by high demand for weight loss drugs, supply shortages of brand-name medications, and the inherent differences between FDA-approved drugs and custom-made compounds.

Here's a breakdown:

What Happened with the FDA and Compounded GLP-1s?

1. Surge in Demand & Shortages:

   • When FDA-approved GLP-1 medications like Ozempic, Wegovy (semaglutide), Mounjaro, and Zepbound (tirzepatide) gained immense popularity for weight loss, the manufacturers faced significant supply shortages.
   • During a drug shortage, compounding pharmacies are sometimes allowed to create versions of the medication to meet patient needs.

2. Compounding Pharmacies Stepped In:

   • Many compounding pharmacies began producing their own versions of semaglutide and tirzepatide. These are not the same as the FDA-approved brand-name drugs.
   • Some online clinics and telehealth services partnered with these compounding pharmacies to offer GLP-1s to patients.

3. FDA's Concerns and Warnings:

   • Unapproved Ingredients: The FDA explicitly warned against compounded versions using semaglutide sodium or semaglutide acetate. The FDA-approved drugs use semaglutide base. The FDA stated that semaglutide salts are not the same active ingredient and have not been evaluated for safety and efficacy. They are not on the FDA's "bulk drug substances list" for compounding.
   • Safety and Efficacy: Compounded drugs do not undergo the rigorous safety, efficacy, and quality testing required for FDA approval. The FDA expressed concerns about potential impurities, incorrect dosages, and the sterility of compounded products, leading to reports of adverse events.
   • "Copying" vs. "Compounding": Compounding is traditionally meant for individual patient needs (e.g., an allergy to an inactive ingredient in the brand-name drug, or a specific dosage not commercially available). The FDA was concerned that some pharmacies were essentially making "copies" of the brand-name drugs for commercial sale rather than legitimate patient-specific compounding during a shortage.
   • Misleading Marketing: The FDA also issued warnings to pharmacies and clinics for misleadingly advertising their compounded drugs as "generic" versions of Ozempic or Wegovy, or implying they were FDA-approved.
   • Enforcement Actions: The FDA has sent warning letters to compounding pharmacies that were illegally marketing or producing unapproved compounded versions of GLP-1s, particularly those using the unapproved salt forms.

Who is Still Operating Legally and Safely?

The FDA's guidance emphasizes patient safety and adherence to specific compounding regulations.

1. FDA-Approved Brand-Name Medications (The Gold Standard):

   • Ozempic (semaglutide, approved for Type 2 diabetes, often prescribed off-label for weight loss)
   • Wegovy (semaglutide, approved for chronic weight management)
   • Mounjaro (tirzepatide, approved for Type 2 diabetes)
   • Zepbound (tirzepatide, approved for chronic weight management)
   • Why it's legal/safe: These are fully FDA-approved drugs, meaning they've undergone extensive clinical trials for safety and efficacy, and their manufacturing processes are strictly regulated. They are prescribed by a licensed healthcare provider and dispensed by a licensed pharmacy.

2. State-Licensed Compounding Pharmacies (Under Strict Conditions):

   • A compounding pharmacy can legally operate if it adheres strictly to state and federal compounding laws. For GLP-1s, this means:
     • Valid Prescription: A specific, individualized prescription from a licensed healthcare provider based on a medical need (e.g., patient cannot tolerate an inactive ingredient in the commercial product).
     • FDA-Approved Ingredients: They must use active pharmaceutical ingredients (APIs) that are FDA-approved or on the FDA's "bulk drug substances list" for compounding. Crucially, as of now, semaglutide sodium/acetate are NOT on this list for this purpose, nor are they the FDA-approved active ingredient in Ozempic/Wegovy. The FDA allows compounding only with semaglutide base when there's a shortage, but even then, it must be for a specific patient's needs, not a general "copy."
     • Quality & Sterility: Adherence to USP (United States Pharmacopeia) compounding standards for sterility, potency, and purity.
     • No Commercial "Copying": They cannot mass-produce these drugs as if they were generic versions of FDA-approved medications.
   • How to check: You can verify a pharmacy's license with your state board of pharmacy. Ask detailed questions about their ingredients and sourcing.

3. Telehealth Services (Partnering with Compliant Pharmacies):

   • Many legitimate telehealth platforms connect patients with licensed prescribers who can write prescriptions for GLP-1s.
   • Legality hinges on their partner pharmacies: If a telehealth service prescribes a compounded GLP-1, it must be partnered with a compounding pharmacy that meets all the strict FDA and state guidelines mentioned above, especially regarding the active ingredients used.
   • Reputable platforms (who often prioritize FDA-approved medications first, but may offer compounded options from verified sources during shortages):
     • Ro (e.g., Ro Body): Focuses on connecting patients with prescribers for FDA-approved medications. They have a stringent approach to sourcing if compounded options are considered.
     • Calibrate: Similar to Ro, often emphasizes FDA-approved medications and comprehensive metabolic health programs.
     • Push Health: Connects patients with independent providers who can prescribe, but the pharmacy choice and their compliance are key.
     • PlushCare: Offers telehealth appointments with doctors who can prescribe medications, including GLP-1s, which would then be filled at traditional pharmacies.

Consumer Advice:

• Prioritize FDA-Approved: Whenever possible, opt for the FDA-approved brand-name medications (Ozempic, Wegovy, Mounjaro, Zepbound) prescribed by a licensed healthcare provider and dispensed by a licensed retail pharmacy.
• Be Skeptical of "Too Good to Be True": Be wary of extremely low prices or providers promising instant access without a thorough medical evaluation.
• Ask Questions: If considering a compounded GLP-1, ask the prescribing provider and the pharmacy:
  • What active pharmaceutical ingredient (API) is being used (e.g., semaglutide base, not semaglutide sodium/acetate)?
  • Is the pharmacy licensed and accredited?
  • What are their quality control and sterility procedures?
  • What are the potential side effects and risks?
• Verify Pharmacy Licensing: Always check a compounding pharmacy's license with your state board of pharmacy.

In summary, while FDA-approved GLP-1s are the safest and most regulated option, certain state-licensed compounding pharmacies can legally produce compounded versions under very strict conditions, primarily using FDA-approved ingredients and only for individualized patient needs. However, the FDA remains highly cautious about the widespread use of compounded GLP-1s, particularly those using unapproved salt forms.